SlideShare a Scribd company logo
1 of 18
Download to read offline
California Dreaming or Reality?
California’s New Paradigm in Chemicals and Products Management Could
Be Coming to a Store Near You.
A Legal Perspective
Webinar of the
American Bar Association
Section of Environment, Energy & Resources
November 15, 2010
Philip A. Moffat
pmoffat@verdantlaw.com
202.828.1233
www.verdantlaw.com
1
Overview of Presentation
• Scope of Regulation
– What’s covered
– Who’s covered
• Regulatory Process
– Requirements
– Exemptions
– Public & regulated community participation
– Timeline
• Dispute Resolution
• Enforcement
• Protection of Confidential Information
• Practical Considerations & Concluding Thoughts
2
What’s Covered?
• Regulation focuses on consumer products with the goal
of encouraging the use of safer alternatives to Chemicals
of Concern.
• It applies to:
– “[A]ll consumer products placed into the stream of
commerce in California,” and
– “all chemicals that exhibit a hazard trait and are
reasonably expected to be contained in products
placed into the stream of commerce in California.”
§§ 69301(b)(1) and 69302.1(a).
3
What’s a Consumer Product?
• Broad definition: “a product or part of the product that is
used, brought, or leased for use by a person for any
purposes.” Health & Safety Code § 25251.
– Individual chemicals packaged as such and placed into the stream
of California commerce are included
– Components also included
• Easier to identify what’s not encompassed:
– Prescription drugs and devices (and packaging)
– Dental restorative materials (and packaging)
– Medical devices (and packaging)
– Food
– Pesticides
– Mercury-containing light bulbs (until 12/31/2011)
4
Other Exclusions
• Products placed into the stream of California
commerce solely for manufacturing those products
that are excluded from the definition of consumer
product.
• Products manufactured in, stored in, or transported
through California for use solely outside California.
• Unintentionally-added chemicals not known to
be present (with due diligence).
§§ 69301(b)-(c).
5
Who Has Obligations?
• Manufacturer
– The producer of a consumer product
– Owner or licensee of the brand name or trademark
• Responsible Entities (RE)
– Owner or licensee of the brand name or trademark
– California importer
– California distributor
– Retailer
– Any party to a contract with a California importer, distributor, or
retailer concerning a consumer product, unless contract specifically
prohibits placing into stream of California commerce
§ 69301.2
6
Safe Harbors
• Remove Product from CA Commerce:
– Individual RE that is not a manufacturer notifies DTSC. § 69301.4(e)(1)
• Need contract w/ supplier ensuring supplier will comply w/ regs
• Others may be continuing to place product on market
– Manufacturer submits a Product Removal Notification or, if
manufacture is also an RE, may provide other substantiation of
removal. Compare § 69301.4(e)(2) w/ § 69301.4(f)(4).
• Manufacturer Removes All Chemicals of Concern from
Product & Files Chemical Removal Notification.
– No chemical replacement or addition may occur. §§ 69301.2(15),
69301.4(f)(4), 69302.5(a) and others.
7
8
Prioritization
• DTSC develops two lists of chemicals:
– Chemicals Under Consideration
– Priority Chemicals
• DTSC develops two lists of products:
– Products Under Consideration
– Priority Products
• DTSC evaluates available information, and may issue
data and information call-ins to manufacturers and
responsible entities. §§ 69301.6, 69302 and 69303.
• Any person may petition to add to lists, but not delete.
§ 69304. No clearly established process for industry to
comment during DTSC review of petition.
9
Prioritization
• Exemptions:
– Federal and/or other California programs address
same public health and environmental threats
throughout the product life cycle – requires “clear &
convincing evidence” from claimant
– No exposure pathway by which chemical might
threaten health or the environment in California –
same burden of proof §§ 69302.1 and 69303.1.
• Public comments prior to finalizing chemical lists.
§§ 69302.2(b) and 69303.2(d).
10
Prioritization
• After a Priority Chemicals List is finalized, DTSC can begin
posting on its website the description and identity of
products determined to contain a Priority Chemical. § 69302.2(b).
• Compressed Timeline for Initial Prioritization:
– Initial proposed list of Chemicals Under Consideration due by
June 1, 2011
– Final initial list of Priority Products due by December 1, 2013
• Summary of Obligations of Responsible Entities (REs):
– Respond to data call-ins. § 69301.6.
– After a product is listed as a Priority Product, must file a Priority
Product Notification with DTSC. § 69303.5.
11
Alternatives Assessment – Tier I
• Applies after a chemical has been added to the final
Chemicals Under Consideration or Priority Chemicals List.
• Responsible entities must notify DTSC prior to placing into CA
commerce any voluntary product reformulations, redesigns, or
replacements that had chemical removed or reduced.
• Tier I AA Report must accompany notice and include:
– Rationale for reformulation
– Reductions in adverse health or environmental impacts
– Hazard traits of any substitute chemicals
• May avoid “regrettable substitutions,” but is it an impediment
to innovation?
§ 69305.1
12
Alternatives Assessment – Tier II
• Lead Assessor Prepares AA - either a Qualified Third-Party Assessment
Entity or Qualified In-House Assessment Entity.
– However, all AAs must be prepared or verified by a third party.
• AA Work Plan:
– Submitted 180 days after posting of final Priority Product list
– Scope of work must include evaluation of same “methodologies and system
boundaries” for both the Priority Product and potential alternatives
– Required elements are extensive
• AA Reports:
– DTSC specifies completion date
– Explain omission of any life cycle segments
– Include rationale for alternative selection or retention of Priority Product
– May propose regulatory response based on the selected alternative
– DTSC determines what, if any, regulatory response is required and sets an
implementation date
• De minimis exemption may be available. §§ 69305.2 – 69305.10
13
Regulatory Response
• DTSC has a range of options and will request public comment on
proposal:
– No response
– Product information to consumers
– Labeling
– End-of-life management
– Use restrictions
– Exposure limits
– Ban
– R&D challenge §§ 69306 – 69306.8.
• REs required to notify retailers about required response, and
DTSC upon completion of response. § 69306.9.
• Exemptions available for certain responses that also conflict
or duplicate CA or federal law or int’l trade agreements ratified by
Senate – require “clear & convincing evidence” from claimant. §
69306.7
14
Dispute Resolution
• Two dispute resolution processes established:
formal and informal. § 69307 – 69307.7.
– Formal applies to challenges of certain regulatory
response actions (e.g., sales prohibitions), as well as
requests for exemptions from many of the potential
responses.
– Informal applies to all other matters (e.g., listings), and
includes opportunity to appeal to DTSC Director.
• Exhaustion of administrative remedies typically
required before seeking judicial review.
15
Enforcement
• REs are jointly & severally liable for noncompliance.
§ 69301.4(f)
• Many options available to DTSC:
– Notice of Noncompliance to all REs w/ a cc to all other
known entities in supply chain. Id.
– Added to Failure to Comply List if not remedied or
exempted after receiving notice. Id.
– Additional fines, penalties, and other enforcement per
Article 8, Chpt. 6.5, Div. 20 Health & Safety Code. § 69301.4(g).
– Manufacturers that fail to respond to information request
may be added to Failure to Respond List. § 69301.6(d)(3).
16
Protection of Confidential Information
• Complicated process for protecting confidential information,
including trade secrets – six pages of regulations, expanding
the process set out in the enabling statute.
• Requires detailed legal analysis of the regulation, Health &
Safety Code section 25257, any other applicable California
statute, and the California Public Records Act as applicable.
• Thirty (30) days to seek judicial review of DTSC determination
of inadequate substantiation/justification of trade secret claim.
• Thirty days to seek judicial review after notice from DTSC that
information is subject to disclosure in response to a Public
Records Act request.
§§ 69310 – 69310.6.
17
Practical Considerations and
Concluding Thoughts
18

More Related Content

What's hot

Overcoming Regulatory, Clinical and Quality Challenges in Developing Combinat...
Overcoming Regulatory, Clinical and Quality Challenges in Developing Combinat...Overcoming Regulatory, Clinical and Quality Challenges in Developing Combinat...
Overcoming Regulatory, Clinical and Quality Challenges in Developing Combinat...Michael Swit
 
Good Automated Manufacturing Practices
Good Automated Manufacturing PracticesGood Automated Manufacturing Practices
Good Automated Manufacturing PracticesPrashant Tomar
 
AN OVERVIEW OF PHARMACEUTICAL PROCESS VALIDATION AND PROCESS CONTROL VARIABLE...
AN OVERVIEW OF PHARMACEUTICAL PROCESS VALIDATION AND PROCESS CONTROL VARIABLE...AN OVERVIEW OF PHARMACEUTICAL PROCESS VALIDATION AND PROCESS CONTROL VARIABLE...
AN OVERVIEW OF PHARMACEUTICAL PROCESS VALIDATION AND PROCESS CONTROL VARIABLE...Mahesh B. Wazade
 
Description & functions of drug regulatory affairs
Description & functions of drug regulatory affairsDescription & functions of drug regulatory affairs
Description & functions of drug regulatory affairsCepal & Co.
 
How to get your COVID-19 Related Medical Device to Market Under FDA Emergency...
How to get your COVID-19 Related Medical Device to Market Under FDA Emergency...How to get your COVID-19 Related Medical Device to Market Under FDA Emergency...
How to get your COVID-19 Related Medical Device to Market Under FDA Emergency...Greenlight Guru
 
Product life cycle management
Product life cycle managementProduct life cycle management
Product life cycle managementVikas Rathee
 
Anda refuse to receive
Anda   refuse to receiveAnda   refuse to receive
Anda refuse to receivesantoshnarla
 
Codex validation Group presentation
Codex validation Group presentationCodex validation Group presentation
Codex validation Group presentationWalter Acevedo
 
Difference between fda 21 cfr part 820 and ISO 13485
Difference between fda 21 cfr part 820 and ISO 13485Difference between fda 21 cfr part 820 and ISO 13485
Difference between fda 21 cfr part 820 and ISO 13485Anil Chaudhari
 
FDA Warning letter
FDA Warning letterFDA Warning letter
FDA Warning letterSridhar S
 
USDMF Preparation and Submissions
USDMF Preparation and SubmissionsUSDMF Preparation and Submissions
USDMF Preparation and SubmissionsGautam Halder
 
Gaining business excellence by leveraging plm platform
Gaining business excellence by leveraging plm platformGaining business excellence by leveraging plm platform
Gaining business excellence by leveraging plm platformSimba Events
 

What's hot (20)

Overcoming Regulatory, Clinical and Quality Challenges in Developing Combinat...
Overcoming Regulatory, Clinical and Quality Challenges in Developing Combinat...Overcoming Regulatory, Clinical and Quality Challenges in Developing Combinat...
Overcoming Regulatory, Clinical and Quality Challenges in Developing Combinat...
 
Good Automated Manufacturing Practices
Good Automated Manufacturing PracticesGood Automated Manufacturing Practices
Good Automated Manufacturing Practices
 
AN OVERVIEW OF PHARMACEUTICAL PROCESS VALIDATION AND PROCESS CONTROL VARIABLE...
AN OVERVIEW OF PHARMACEUTICAL PROCESS VALIDATION AND PROCESS CONTROL VARIABLE...AN OVERVIEW OF PHARMACEUTICAL PROCESS VALIDATION AND PROCESS CONTROL VARIABLE...
AN OVERVIEW OF PHARMACEUTICAL PROCESS VALIDATION AND PROCESS CONTROL VARIABLE...
 
Description & functions of drug regulatory affairs
Description & functions of drug regulatory affairsDescription & functions of drug regulatory affairs
Description & functions of drug regulatory affairs
 
Computerized system validation
Computerized system validationComputerized system validation
Computerized system validation
 
FDA Regulations
FDA RegulationsFDA Regulations
FDA Regulations
 
Gamp5 new
Gamp5 newGamp5 new
Gamp5 new
 
How to get your COVID-19 Related Medical Device to Market Under FDA Emergency...
How to get your COVID-19 Related Medical Device to Market Under FDA Emergency...How to get your COVID-19 Related Medical Device to Market Under FDA Emergency...
How to get your COVID-19 Related Medical Device to Market Under FDA Emergency...
 
Gamp 5 overview by jaya prakash ra
Gamp 5 overview by jaya prakash raGamp 5 overview by jaya prakash ra
Gamp 5 overview by jaya prakash ra
 
DMF by Anthony Crasto
DMF by Anthony CrastoDMF by Anthony Crasto
DMF by Anthony Crasto
 
Product life cycle management
Product life cycle managementProduct life cycle management
Product life cycle management
 
FDA Guidance on Facing Sterile Manufacturing Inspections.
FDA Guidance on Facing Sterile Manufacturing  Inspections.FDA Guidance on Facing Sterile Manufacturing  Inspections.
FDA Guidance on Facing Sterile Manufacturing Inspections.
 
Anda refuse to receive
Anda   refuse to receiveAnda   refuse to receive
Anda refuse to receive
 
Codex validation Group presentation
Codex validation Group presentationCodex validation Group presentation
Codex validation Group presentation
 
Difference between fda 21 cfr part 820 and ISO 13485
Difference between fda 21 cfr part 820 and ISO 13485Difference between fda 21 cfr part 820 and ISO 13485
Difference between fda 21 cfr part 820 and ISO 13485
 
FDA Warning letter
FDA Warning letterFDA Warning letter
FDA Warning letter
 
USDMF Preparation and Submissions
USDMF Preparation and SubmissionsUSDMF Preparation and Submissions
USDMF Preparation and Submissions
 
Presentation on EU GMP Annex 16 - Certification by QP
Presentation on EU GMP Annex 16 - Certification by QPPresentation on EU GMP Annex 16 - Certification by QP
Presentation on EU GMP Annex 16 - Certification by QP
 
Gaining business excellence by leveraging plm platform
Gaining business excellence by leveraging plm platformGaining business excellence by leveraging plm platform
Gaining business excellence by leveraging plm platform
 
1234 ingles
1234 ingles1234 ingles
1234 ingles
 

Similar to California's Draft Green Chemistry Regulations

Overview of FDA Regulation of Devices & Diagnostics
Overview of FDA Regulation of Devices & DiagnosticsOverview of FDA Regulation of Devices & Diagnostics
Overview of FDA Regulation of Devices & DiagnosticsMichael Swit
 
BlueScape & Dentons New Prop 65 Warning Requirements Webinar 011717
BlueScape & Dentons New Prop 65 Warning Requirements Webinar 011717BlueScape & Dentons New Prop 65 Warning Requirements Webinar 011717
BlueScape & Dentons New Prop 65 Warning Requirements Webinar 011717BlueScape
 
Devices Sponsor Information Day: 5 - Post-market - Recalls and non-recall act...
Devices Sponsor Information Day: 5 - Post-market - Recalls and non-recall act...Devices Sponsor Information Day: 5 - Post-market - Recalls and non-recall act...
Devices Sponsor Information Day: 5 - Post-market - Recalls and non-recall act...TGA Australia
 
Presentation Recall of Therapeutic Goods – Overview
Presentation Recall of Therapeutic Goods – Overview Presentation Recall of Therapeutic Goods – Overview
Presentation Recall of Therapeutic Goods – Overview TGA Australia
 
COMBINATION PRODUCTS – Perspectives on FDA Regulation
COMBINATION PRODUCTS – Perspectives on FDA RegulationCOMBINATION PRODUCTS – Perspectives on FDA Regulation
COMBINATION PRODUCTS – Perspectives on FDA RegulationMichael Swit
 
BlueScape & StilesPomeroy LLP New Proposition 65 Warning Requirements are He...
 BlueScape & StilesPomeroy LLP New Proposition 65 Warning Requirements are He... BlueScape & StilesPomeroy LLP New Proposition 65 Warning Requirements are He...
BlueScape & StilesPomeroy LLP New Proposition 65 Warning Requirements are He...BlueScape
 
Working with Partners and Customers on Your Regulatory Strategy
Working with Partners and Customers on Your Regulatory StrategyWorking with Partners and Customers on Your Regulatory Strategy
Working with Partners and Customers on Your Regulatory StrategyDavid Glass
 
Recalls: The First Smoke of A Mass Tort -- Overview of a Recall of an FDA-Reg...
Recalls: The First Smoke of A Mass Tort -- Overview of a Recall of an FDA-Reg...Recalls: The First Smoke of A Mass Tort -- Overview of a Recall of an FDA-Reg...
Recalls: The First Smoke of A Mass Tort -- Overview of a Recall of an FDA-Reg...Michael Swit
 
FDA Enforcement -- the Perils of Inadequate Compliance
FDA Enforcement -- the Perils of Inadequate ComplianceFDA Enforcement -- the Perils of Inadequate Compliance
FDA Enforcement -- the Perils of Inadequate ComplianceMichael Swit
 
FDA Enforcement -- the Perils of Inadequate Compliance
FDA Enforcement -- the Perils of Inadequate ComplianceFDA Enforcement -- the Perils of Inadequate Compliance
FDA Enforcement -- the Perils of Inadequate ComplianceMichael Swit
 
Compliance in PLM Webinar 1
Compliance in PLM Webinar 1Compliance in PLM Webinar 1
Compliance in PLM Webinar 1Stephen Porter
 
ANDAs, OTCs, Orphans and Cosmetics – Key Issues
ANDAs, OTCs, Orphans and Cosmetics – Key IssuesANDAs, OTCs, Orphans and Cosmetics – Key Issues
ANDAs, OTCs, Orphans and Cosmetics – Key IssuesMichael Swit
 
Bringing Legacy Combination Products into Compliance with 21 CFR Part 4
Bringing Legacy Combination Products into Compliance with 21 CFR Part 4Bringing Legacy Combination Products into Compliance with 21 CFR Part 4
Bringing Legacy Combination Products into Compliance with 21 CFR Part 4Peter Dellva
 
Responding Effectively to FDA 483 Observations & Warning Letters
Responding Effectively to FDA 483 Observations & Warning LettersResponding Effectively to FDA 483 Observations & Warning Letters
Responding Effectively to FDA 483 Observations & Warning LettersMaetrics
 
ANDAs, OTCs, Orphans and Cosmetics – Key Issues
ANDAs, OTCs, Orphans and Cosmetics – Key IssuesANDAs, OTCs, Orphans and Cosmetics – Key Issues
ANDAs, OTCs, Orphans and Cosmetics – Key IssuesMichael Swit
 
Post marketing surveillance april 2011
Post marketing surveillance april 2011Post marketing surveillance april 2011
Post marketing surveillance april 2011Erik Vollebregt
 
Conflict Mineral Compliance Toolkit For Executives
Conflict Mineral Compliance Toolkit For Executives Conflict Mineral Compliance Toolkit For Executives
Conflict Mineral Compliance Toolkit For Executives Matt Whitteker
 
Compliance in PLM Webinar 3
Compliance in PLM Webinar 3Compliance in PLM Webinar 3
Compliance in PLM Webinar 3Stephen Porter
 

Similar to California's Draft Green Chemistry Regulations (20)

Overview of FDA Regulation of Devices & Diagnostics
Overview of FDA Regulation of Devices & DiagnosticsOverview of FDA Regulation of Devices & Diagnostics
Overview of FDA Regulation of Devices & Diagnostics
 
BlueScape & Dentons New Prop 65 Warning Requirements Webinar 011717
BlueScape & Dentons New Prop 65 Warning Requirements Webinar 011717BlueScape & Dentons New Prop 65 Warning Requirements Webinar 011717
BlueScape & Dentons New Prop 65 Warning Requirements Webinar 011717
 
Regulatory 101
Regulatory 101 Regulatory 101
Regulatory 101
 
Devices Sponsor Information Day: 5 - Post-market - Recalls and non-recall act...
Devices Sponsor Information Day: 5 - Post-market - Recalls and non-recall act...Devices Sponsor Information Day: 5 - Post-market - Recalls and non-recall act...
Devices Sponsor Information Day: 5 - Post-market - Recalls and non-recall act...
 
Presentation Recall of Therapeutic Goods – Overview
Presentation Recall of Therapeutic Goods – Overview Presentation Recall of Therapeutic Goods – Overview
Presentation Recall of Therapeutic Goods – Overview
 
COMBINATION PRODUCTS – Perspectives on FDA Regulation
COMBINATION PRODUCTS – Perspectives on FDA RegulationCOMBINATION PRODUCTS – Perspectives on FDA Regulation
COMBINATION PRODUCTS – Perspectives on FDA Regulation
 
BlueScape & StilesPomeroy LLP New Proposition 65 Warning Requirements are He...
 BlueScape & StilesPomeroy LLP New Proposition 65 Warning Requirements are He... BlueScape & StilesPomeroy LLP New Proposition 65 Warning Requirements are He...
BlueScape & StilesPomeroy LLP New Proposition 65 Warning Requirements are He...
 
Working with Partners and Customers on Your Regulatory Strategy
Working with Partners and Customers on Your Regulatory StrategyWorking with Partners and Customers on Your Regulatory Strategy
Working with Partners and Customers on Your Regulatory Strategy
 
Recalls: The First Smoke of A Mass Tort -- Overview of a Recall of an FDA-Reg...
Recalls: The First Smoke of A Mass Tort -- Overview of a Recall of an FDA-Reg...Recalls: The First Smoke of A Mass Tort -- Overview of a Recall of an FDA-Reg...
Recalls: The First Smoke of A Mass Tort -- Overview of a Recall of an FDA-Reg...
 
FDA Enforcement -- the Perils of Inadequate Compliance
FDA Enforcement -- the Perils of Inadequate ComplianceFDA Enforcement -- the Perils of Inadequate Compliance
FDA Enforcement -- the Perils of Inadequate Compliance
 
FDA Enforcement -- the Perils of Inadequate Compliance
FDA Enforcement -- the Perils of Inadequate ComplianceFDA Enforcement -- the Perils of Inadequate Compliance
FDA Enforcement -- the Perils of Inadequate Compliance
 
Compliance in PLM Webinar 1
Compliance in PLM Webinar 1Compliance in PLM Webinar 1
Compliance in PLM Webinar 1
 
ANDAs, OTCs, Orphans and Cosmetics – Key Issues
ANDAs, OTCs, Orphans and Cosmetics – Key IssuesANDAs, OTCs, Orphans and Cosmetics – Key Issues
ANDAs, OTCs, Orphans and Cosmetics – Key Issues
 
Bringing Legacy Combination Products into Compliance with 21 CFR Part 4
Bringing Legacy Combination Products into Compliance with 21 CFR Part 4Bringing Legacy Combination Products into Compliance with 21 CFR Part 4
Bringing Legacy Combination Products into Compliance with 21 CFR Part 4
 
Responding Effectively to FDA 483 Observations & Warning Letters
Responding Effectively to FDA 483 Observations & Warning LettersResponding Effectively to FDA 483 Observations & Warning Letters
Responding Effectively to FDA 483 Observations & Warning Letters
 
ANDAs, OTCs, Orphans and Cosmetics – Key Issues
ANDAs, OTCs, Orphans and Cosmetics – Key IssuesANDAs, OTCs, Orphans and Cosmetics – Key Issues
ANDAs, OTCs, Orphans and Cosmetics – Key Issues
 
Post marketing surveillance april 2011
Post marketing surveillance april 2011Post marketing surveillance april 2011
Post marketing surveillance april 2011
 
Conflict Mineral Compliance Toolkit For Executives
Conflict Mineral Compliance Toolkit For Executives Conflict Mineral Compliance Toolkit For Executives
Conflict Mineral Compliance Toolkit For Executives
 
RECALL.pptx
RECALL.pptxRECALL.pptx
RECALL.pptx
 
Compliance in PLM Webinar 3
Compliance in PLM Webinar 3Compliance in PLM Webinar 3
Compliance in PLM Webinar 3
 

California's Draft Green Chemistry Regulations

  • 1. California Dreaming or Reality? California’s New Paradigm in Chemicals and Products Management Could Be Coming to a Store Near You. A Legal Perspective Webinar of the American Bar Association Section of Environment, Energy & Resources November 15, 2010 Philip A. Moffat pmoffat@verdantlaw.com 202.828.1233 www.verdantlaw.com 1
  • 2. Overview of Presentation • Scope of Regulation – What’s covered – Who’s covered • Regulatory Process – Requirements – Exemptions – Public & regulated community participation – Timeline • Dispute Resolution • Enforcement • Protection of Confidential Information • Practical Considerations & Concluding Thoughts 2
  • 3. What’s Covered? • Regulation focuses on consumer products with the goal of encouraging the use of safer alternatives to Chemicals of Concern. • It applies to: – “[A]ll consumer products placed into the stream of commerce in California,” and – “all chemicals that exhibit a hazard trait and are reasonably expected to be contained in products placed into the stream of commerce in California.” §§ 69301(b)(1) and 69302.1(a). 3
  • 4. What’s a Consumer Product? • Broad definition: “a product or part of the product that is used, brought, or leased for use by a person for any purposes.” Health & Safety Code § 25251. – Individual chemicals packaged as such and placed into the stream of California commerce are included – Components also included • Easier to identify what’s not encompassed: – Prescription drugs and devices (and packaging) – Dental restorative materials (and packaging) – Medical devices (and packaging) – Food – Pesticides – Mercury-containing light bulbs (until 12/31/2011) 4
  • 5. Other Exclusions • Products placed into the stream of California commerce solely for manufacturing those products that are excluded from the definition of consumer product. • Products manufactured in, stored in, or transported through California for use solely outside California. • Unintentionally-added chemicals not known to be present (with due diligence). §§ 69301(b)-(c). 5
  • 6. Who Has Obligations? • Manufacturer – The producer of a consumer product – Owner or licensee of the brand name or trademark • Responsible Entities (RE) – Owner or licensee of the brand name or trademark – California importer – California distributor – Retailer – Any party to a contract with a California importer, distributor, or retailer concerning a consumer product, unless contract specifically prohibits placing into stream of California commerce § 69301.2 6
  • 7. Safe Harbors • Remove Product from CA Commerce: – Individual RE that is not a manufacturer notifies DTSC. § 69301.4(e)(1) • Need contract w/ supplier ensuring supplier will comply w/ regs • Others may be continuing to place product on market – Manufacturer submits a Product Removal Notification or, if manufacture is also an RE, may provide other substantiation of removal. Compare § 69301.4(e)(2) w/ § 69301.4(f)(4). • Manufacturer Removes All Chemicals of Concern from Product & Files Chemical Removal Notification. – No chemical replacement or addition may occur. §§ 69301.2(15), 69301.4(f)(4), 69302.5(a) and others. 7
  • 8. 8
  • 9. Prioritization • DTSC develops two lists of chemicals: – Chemicals Under Consideration – Priority Chemicals • DTSC develops two lists of products: – Products Under Consideration – Priority Products • DTSC evaluates available information, and may issue data and information call-ins to manufacturers and responsible entities. §§ 69301.6, 69302 and 69303. • Any person may petition to add to lists, but not delete. § 69304. No clearly established process for industry to comment during DTSC review of petition. 9
  • 10. Prioritization • Exemptions: – Federal and/or other California programs address same public health and environmental threats throughout the product life cycle – requires “clear & convincing evidence” from claimant – No exposure pathway by which chemical might threaten health or the environment in California – same burden of proof §§ 69302.1 and 69303.1. • Public comments prior to finalizing chemical lists. §§ 69302.2(b) and 69303.2(d). 10
  • 11. Prioritization • After a Priority Chemicals List is finalized, DTSC can begin posting on its website the description and identity of products determined to contain a Priority Chemical. § 69302.2(b). • Compressed Timeline for Initial Prioritization: – Initial proposed list of Chemicals Under Consideration due by June 1, 2011 – Final initial list of Priority Products due by December 1, 2013 • Summary of Obligations of Responsible Entities (REs): – Respond to data call-ins. § 69301.6. – After a product is listed as a Priority Product, must file a Priority Product Notification with DTSC. § 69303.5. 11
  • 12. Alternatives Assessment – Tier I • Applies after a chemical has been added to the final Chemicals Under Consideration or Priority Chemicals List. • Responsible entities must notify DTSC prior to placing into CA commerce any voluntary product reformulations, redesigns, or replacements that had chemical removed or reduced. • Tier I AA Report must accompany notice and include: – Rationale for reformulation – Reductions in adverse health or environmental impacts – Hazard traits of any substitute chemicals • May avoid “regrettable substitutions,” but is it an impediment to innovation? § 69305.1 12
  • 13. Alternatives Assessment – Tier II • Lead Assessor Prepares AA - either a Qualified Third-Party Assessment Entity or Qualified In-House Assessment Entity. – However, all AAs must be prepared or verified by a third party. • AA Work Plan: – Submitted 180 days after posting of final Priority Product list – Scope of work must include evaluation of same “methodologies and system boundaries” for both the Priority Product and potential alternatives – Required elements are extensive • AA Reports: – DTSC specifies completion date – Explain omission of any life cycle segments – Include rationale for alternative selection or retention of Priority Product – May propose regulatory response based on the selected alternative – DTSC determines what, if any, regulatory response is required and sets an implementation date • De minimis exemption may be available. §§ 69305.2 – 69305.10 13
  • 14. Regulatory Response • DTSC has a range of options and will request public comment on proposal: – No response – Product information to consumers – Labeling – End-of-life management – Use restrictions – Exposure limits – Ban – R&D challenge §§ 69306 – 69306.8. • REs required to notify retailers about required response, and DTSC upon completion of response. § 69306.9. • Exemptions available for certain responses that also conflict or duplicate CA or federal law or int’l trade agreements ratified by Senate – require “clear & convincing evidence” from claimant. § 69306.7 14
  • 15. Dispute Resolution • Two dispute resolution processes established: formal and informal. § 69307 – 69307.7. – Formal applies to challenges of certain regulatory response actions (e.g., sales prohibitions), as well as requests for exemptions from many of the potential responses. – Informal applies to all other matters (e.g., listings), and includes opportunity to appeal to DTSC Director. • Exhaustion of administrative remedies typically required before seeking judicial review. 15
  • 16. Enforcement • REs are jointly & severally liable for noncompliance. § 69301.4(f) • Many options available to DTSC: – Notice of Noncompliance to all REs w/ a cc to all other known entities in supply chain. Id. – Added to Failure to Comply List if not remedied or exempted after receiving notice. Id. – Additional fines, penalties, and other enforcement per Article 8, Chpt. 6.5, Div. 20 Health & Safety Code. § 69301.4(g). – Manufacturers that fail to respond to information request may be added to Failure to Respond List. § 69301.6(d)(3). 16
  • 17. Protection of Confidential Information • Complicated process for protecting confidential information, including trade secrets – six pages of regulations, expanding the process set out in the enabling statute. • Requires detailed legal analysis of the regulation, Health & Safety Code section 25257, any other applicable California statute, and the California Public Records Act as applicable. • Thirty (30) days to seek judicial review of DTSC determination of inadequate substantiation/justification of trade secret claim. • Thirty days to seek judicial review after notice from DTSC that information is subject to disclosure in response to a Public Records Act request. §§ 69310 – 69310.6. 17